GlassScriptPhysician profile
Honor Fullerton Stone
NPI 1962425496
$15,041.55
in general payments reported to CMS, 2019-2025
23 companies · $588 in 2025
The $588 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $2,153 · 2021: $796 · 2022: $724 · 2023: $358 · 2024: $215 · 2025: $588.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,146 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,146.25 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $10,973.56 | 2019-2024 | Jublia, Arazlo, Cabtreo |
| Allergan, INC. | $630.64 | 2019-2022 | |
| Galderma Laboratories, L.P. | $359.32 | 2020-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $349.20 | 2019-2025 | Dupixent |
| Abbvie INC. | $307.62 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $285.60 | 2020-2025 | Tremfya, Stelara |
| Ucb, INC. | $270.49 | 2019-2022 | |
| Genzyme Corporation | $256.39 | 2019-2025 | |
| Almirall LLC | $221.07 | 2019-2025 | Klisyri |
| Solta Medical, A Division of Bausch Health US, LLC | $207.42 | 2019 | |
| Leo Pharma INC. | $200.16 | 2019-2023 | Adbry |
| Pfizer INC. | $182.43 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $179.11 | 2019-2024 | Winlevi, Absorica Ld |
| Revance Therapeutics, INC. | $133.00 | 2024-2025 | Daxxify, Daxi |
| Lilly USA, LLC | $115.50 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $93.99 | 2022-2025 | Opzelura |
| Merz North America, INC. | $59.83 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $50.02 | 2022-2023 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $45.68 | 2023-2025 | Zoryve |
| Amgen INC. | $44.08 | 2020-2022 | |
| Biofrontera INC. | $31.57 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $27.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Honor Fullerton Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.